NCT06683820

Brief Summary

The investigators report a case of the simultaneous use of split liver transplantation (SLT), domino liver transplantation (DLT) and auxiliary liver transplantation (ALT) to achieve "one donor for three recipients".

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Apr 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 2, 2023

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 2, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 2, 2024

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

November 8, 2024

Completed
4 days until next milestone

First Posted

Study publicly available on registry

November 12, 2024

Completed
Last Updated

December 5, 2024

Status Verified

November 1, 2024

Enrollment Period

1 year

First QC Date

November 8, 2024

Last Update Submit

December 2, 2024

Conditions

Hepatocellular Carcinoma (HCC)

Keywords

Split liver transplantationDomino liver transplantationAuxiliary liver transplantationArgininemiaCirrhosisHepatocellular carcinoma

Outcome Measures

Primary Outcomes (1)

  • Postoperative survival time

    The duration of time a patient survives after undergoing a surgical procedure.

    2023/04-2024/04

Study Arms (1)

Triple Recipient Strategy

The simultaneous use of split liver transplantation (SLT), domino liver transplantation (DLT) and auxiliary liver transplantation (ALT)

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Recipient 1 was a 57-year-old female who was admitted due to hepatitis C virus-related liver cirrhosis. Recipient 2 was a 13-year-old male diagnosed with argininemia, who had a Model for End-Stage Liver Disease score of 12. Recipient 3, a 70-year-old adult male, was diagnosed with HCC and had no prior history of cirrhosis.

You may qualify if:

  • liver cirrhosis
  • argininemia
  • hepatocellular carcinoma

You may not qualify if:

  • Patients who do not require an allogeneic liver transplantation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

2ndAffiliated Hospital, School of Medicine, Zhejiang University

Hangzhou, Zhejiang, 310009, China

Location

MeSH Terms

Conditions

Carcinoma, HepatocellularHyperargininemiaFibrosis

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsLiver NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesLiver DiseasesUrea Cycle Disorders, InbornBrain Diseases, Metabolic, InbornBrain Diseases, MetabolicBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesAmino Acid Metabolism, Inborn ErrorsMetabolism, Inborn ErrorsGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesMetabolic DiseasesNutritional and Metabolic DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Target Duration
1 Year
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 8, 2024

First Posted

November 12, 2024

Study Start

April 2, 2023

Primary Completion

April 2, 2024

Study Completion

April 2, 2024

Last Updated

December 5, 2024

Record last verified: 2024-11

Locations

CN(1)